Kyuhyun Lee

USPTO Granted Patents = 10 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 6.1

ph-index = 5

Forward Citations = 44(Granted Patents)

Company Filing History:

7 out of 27

Mogam Biotechnology Research Institute

patents

3 out of 260

The Green Cross Corporation

patents

2 out of 16

Mogam Institute for Biomedical Research

Medigenebio Corporation

patents

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11052135 - Methods and compositions for treating hunter syndrome (2021-07-06),

2. 10851175 - Anti-mesothelin antibody and composition comprising the same (2020-12-01),

3. 10752697 - Anti-glypican 3 antibody and pharmaceutical composition containing the same (2020-08-25),

4. 10066215 - Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same (2018-09-04),

5. 9493745 - Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same (2016-11-15),

6. 9018182 - Tumor specific promoter and oncolytic virus vector comprising the same (2015-04-28),

7. 8628956 - Expression vector suitable for expression of a coding sequence for gene therapy (2014-01-14),

8. 8617875 - Expression vector suitable for expression of a coding sequence for gene therapy (2013-12-31),

9. 8569051 - Expression vector for gene therapy (2013-10-29),

10. 8309698 - Expression vector suitable for expression of a coding sequence for gene therapy (2012-11-13),

Title: The Innovations of Inventor Kyuhyun Lee

Introduction

Kyuhyun Lee, an accomplished inventor based in Yongin-si, South Korea, has made significant contributions to the fields of biotechnology and medicine. With a portfolio of 10 patents, his work reflects a commitment to advancing medical treatments and therapies, especially in the realm of rare diseases and cancer care.

Latest Patents

Kyuhyun Lee's latest inventions include groundbreaking methods and compositions for treating Hunter Syndrome. This innovative approach offers compositions and methods for the central nervous system (CNS) delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein. His invention not only aims to alleviate symptoms in the brain and spinal cord but also effectively addresses issues in peripheral tissues such as the heart, liver, spleen, lung, and kidney.

Additionally, he has developed a highly specific antibody that targets mesothelin (MSLN). This invention includes a nucleic acid encoding the antibody, a vector, and a host cell containing the nucleic acid. The resulting antibody demonstrates high affinity and specificity to mesothelin, opening doors for effective treatment and diagnosis of cancer and tumor diseases through its incorporation in pharmaceutical compositions.

Career Highlights

Throughout his career, Kyuhyun Lee has held positions at notable institutions, including Mogam Biotechnology Research Institute and Green Cross Corporation. His work has been characterized by a focus on innovative biotherapeutics and the development of effective treatment methodologies.

Collaborations

Kyuhyun has also collaborated with distinguished professionals, including Daekyung Koh and Seongtae Yun. These partnerships have facilitated advancements in research and development, contributing to the success of his patented inventions.

Conclusion

Kyuhyun Lee stands out as a visionary inventor dedicated to improving medical treatments through innovation. His patents, particularly in the treatment of Hunter Syndrome and cancer therapies, underscore his expertise and commitment to bettering human health. Through his work, Lee continues to influence the fields of biotechnology and medicine significantly, inspiring future advancements and research.

This text is generated by artificial intelligence and may not be accurate.